Bruce I. Sachs - 12 Apr 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
12 Apr 2023
Net transactions value
-$5,422,840
Form type
4
Filing time
14 Apr 2023, 16:14:39 UTC
Previous filing
02 Feb 2023
Next filing
18 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $1,536,582 +21,300 +52% $72.14* 62,510 12 Apr 2023 Direct
transaction VRTX Common Stock Sale $949,921 -2,917 -4.7% $325.65 59,593 12 Apr 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $3,381,146 -10,357 -17% $326.46 49,236 12 Apr 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $2,628,354 -8,026 -16% $327.48 41,210 12 Apr 2023 Direct F1, F2, F5
transaction VRTX Common Stock Gift $0 -1,210 -2.9% $0.000000 40,000 13 Apr 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -21,300 -100% $0.000000* 0 12 Apr 2023 Common Stock 21,300 $72.14 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.
F2 Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $325.65 (range $325.00 to $325.99).
F4 Open market sales reported on this line occurred at a weighted average price of $326.46 (range $326.00 to $326.97).
F5 Open market sales reported on this line occurred at a weighted average price of $327.48 (range $327.00 to $327.93).
F6 Fully vested